Department of Neurology, School of Medicine, University of California, Davis, California, 95817.
Institute for Pediatric Regenerative Medicine (IPRM), Shriners Hospitals for Children/UC Davis School of Medicine, Sacramento, California, 95817.
J Neurosci. 2021 Feb 24;41(8):1650-1664. doi: 10.1523/JNEUROSCI.2386-20.2021. Epub 2021 Jan 15.
Promoting oligodendrocyte (OL) differentiation represents a promising option for remyelination therapy for treating the demyelinating disease multiple sclerosis (MS). The Wnt effector transcription factor 7-like 2 (TCF7l2) was upregulated in MS lesions and had been proposed to inhibit OL differentiation. Recent data suggest the opposite yet underlying mechanisms remain elusive. Here, we unravel a previously unappreciated function of TCF7l2 in controlling autocrine bone morphogenetic protein (BMP)4-mediated signaling. Disrupting TCF7l2 in mice of both sexes results in oligodendroglial-specific BMP4 upregulation and canonical BMP4 signaling activation Mechanistically, TCF7l2 binds to gene regulatory element and directly represses its transcriptional activity. Functionally, enforced TCF7l2 expression promotes OL differentiation by reducing autocrine BMP4 secretion and dampening BMP4 signaling. Importantly, compound genetic disruption demonstrates that oligodendroglial-specific BMP4 deletion rescues arrested OL differentiation elicited by TCF7l2 disruption Collectively, our study reveals a novel connection between TCF7l2 and BMP4 in oligodendroglial lineage and provides new insights into augmenting TCF7l2 for promoting remyelination in demyelinating disorders such as MS. Incomplete or failed myelin repairs, primarily resulting from the arrested differentiation of myelin-forming oligodendrocytes (OLs) from oligodendroglial progenitor cells, is one of the major reasons for neurologic progression in people affected by multiple sclerosis (MS). Using culture systems and animal models, this study unraveled a previously unrecognized autocrine regulation of bone morphogenetic protein (BMP)4-mediated signaling by the Wnt effector transcription factor 7-like 2 (TCF7l2). We showed for the first time that TCF7l2 promotes oligodendroglial differentiation by repressing BMP4-mediated activity, which is dysregulated in MS lesions. Our study suggests that elevating TCF7l2 expression may be possible in overcoming arrested oligodendroglial differentiation as observed in MS patients.
促进少突胶质细胞(OL)分化代表了治疗脱髓鞘疾病多发性硬化症(MS)的髓鞘再生治疗的一个很有前景的选择。Wnt 效应转录因子 7 样 2(TCF7l2)在 MS 病变中上调,并被提议抑制 OL 分化。最近的数据表明情况正好相反,但潜在的机制仍不清楚。在这里,我们揭示了 TCF7l2 在控制自分泌骨形态发生蛋白(BMP)4 介导的信号中的一个以前未被认识到的功能。在雌雄小鼠中破坏 TCF7l2 会导致少突胶质细胞特异性 BMP4 上调和经典 BMP4 信号激活。从机制上讲,TCF7l2 结合到 基因调控元件并直接抑制其转录活性。从功能上讲,强制表达 TCF7l2 通过减少自分泌 BMP4 分泌和抑制 BMP4 信号来促进 OL 分化。重要的是,复合遗传破坏表明,少突胶质细胞特异性 BMP4 缺失可挽救 TCF7l2 破坏引起的 OL 分化停滞。总的来说,我们的研究揭示了 TCF7l2 和 BMP4 在少突胶质细胞谱系中的新联系,并为增强 TCF7l2 促进脱髓鞘疾病(如 MS)中的髓鞘再生提供了新的见解。不完全或失败的髓鞘修复,主要是由于少突胶质细胞前体细胞中髓鞘形成少突胶质细胞(OL)的分化停滞,是影响多发性硬化症(MS)患者神经进展的主要原因之一。本研究使用 培养系统和 动物模型,揭示了 Wnt 效应转录因子 7 样 2(TCF7l2)对骨形态发生蛋白(BMP)4 介导的信号的以前未被认识到的自分泌调节。我们首次表明,TCF7l2 通过抑制 BMP4 介导的活性来促进少突胶质细胞分化,而 BMP4 介导的活性在 MS 病变中失调。我们的研究表明,在 MS 患者中观察到的 OL 分化停滞,可能可以通过提高 TCF7l2 的表达来克服。